Acidaminococcus
PD-1 inhibitor
Turicibacter
clinical efficacy
gut microbiota
immune checkpoint inhibitors
immune-related adverse events
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
02
2023
accepted:
03
04
2023
medline:
22
5
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
epublish
Résumé
Immune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, such as age and race. Gut microbiota composition in Japanese cancer patients and the efficacy of immunotherapy remain unknown. We investigated the gut microbiota of 26 patients with solid tumors prior to immune checkpoint inhibitor monotherapy to identify bacteria involved in the efficacy of these drugs and immune-related adverse events (irAEs). The genera Our Study suggests that the analysis of the gut microbiota may provide future predictive markers for the efficacy of cancer immunotherapy or the selection of candidates for fecal transplantation for cancer immunotherapy.
Identifiants
pubmed: 37207204
doi: 10.3389/fimmu.2023.1164724
pmc: PMC10189048
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1164724Informations de copyright
Copyright © 2023 Hamada, Isobe, Hattori, Hosonuma, Baba, Murayama, Narikawa, Toyoda, Funayama, Tajima, Shida, Hirasawa, Tsurui, Ariizumi, Ishiguro, Suzuki, Ohkuma, Kubota, Sambe, Tsuji, Wada, Kiuchi, Kobayashi, Kuramasu, Horiike, Kim, Tsunoda and Yoshimura.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Science. 2021 Feb 5;371(6529):602-609
pubmed: 33303685
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
Nat Rev Immunol. 2019 May;19(5):305-323
pubmed: 30858494
Gastroenterology. 2021 Jan;160(2):600-613
pubmed: 33253684
Cell Host Microbe. 2015 Jun 10;17(6):852
pubmed: 26308884
Anticancer Res. 2021 Oct;41(10):4985-4993
pubmed: 34593446
Nature. 2011 May 12;473(7346):174-80
pubmed: 21508958
Nat Rev Cancer. 2013 Nov;13(11):800-12
pubmed: 24132111
DNA Res. 2016 Apr;23(2):125-33
pubmed: 26951067
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):321-322
pubmed: 28442782
Nat Commun. 2020 May 1;11(1):2168
pubmed: 32358520
Nat Commun. 2016 Feb 02;7:10391
pubmed: 26837003
J Natl Cancer Inst. 2013 Dec 18;105(24):1907-11
pubmed: 24316595
Nat Med. 2018 Dec;24(12):1804-1808
pubmed: 30420754
Gastroenterology. 2011 Jul;141(1):227-36
pubmed: 21621540
FEMS Microbiol Ecol. 2012 Mar;79(3):763-72
pubmed: 22126419
J Hepatocell Carcinoma. 2021 Jul 24;8:809-822
pubmed: 34336726
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
J Gastroenterol. 2017 Jan;52(1):1-8
pubmed: 27448578
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
World J Gastroenterol. 2015 Mar 7;21(9):2759-69
pubmed: 25759547
PLoS Biol. 2016 Aug 19;14(8):e1002533
pubmed: 27541692
Cancer Immunol Res. 2020 Oct;8(10):1251-1261
pubmed: 32855157
Nature. 2017 Nov 23;551(7681):507-511
pubmed: 29143816
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Cell Host Microbe. 2014 Mar 12;15(3):382-392
pubmed: 24629344
N Engl J Med. 2012 Jun 28;366(26):2517-9
pubmed: 22658126
Front Endocrinol (Lausanne). 2022 Aug 11;13:958218
pubmed: 36034447
N Engl J Med. 2016 Dec 15;375(24):2369-2379
pubmed: 27974040